No results for ‘’
Pfizer Ltd
₹4020.70
(0.37%)
Tue, 22 Sept 2026, 08:14 pm
Health Technology
Pharmaceuticals: Major
24.5KPfizer Ratios
| Particulars | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 38.60 | 21.73 | 5.68 | 4.66 | 20.79 | 21.65 | 19.42 | 6.29 | 17.08 | 101.70 | 26.80 | 25.71 | 27.77 | 35.41 | 36.17 | 41.57 | 32.50 | 25.40 | 34.80 | 23.86 |
| Price to book ratio | 7.14 | 5.70 | 2.97 | 1.55 | 2.86 | 3.14 | 2.75 | 1.87 | 5.73 | 5.17 | 3.78 | 3.58 | 3.73 | 5.04 | 5.42 | 8.64 | 6.95 | 4.94 | 5.34 | 4.34 |
| Price to sales ratio | 4.26 | 3.33 | 2.77 | 1.98 | 3.58 | 4.17 | 3.28 | 3.02 | 3.40 | 5.51 | 4.06 | 4.40 | 5.08 | 7.30 | 8.56 | 9.24 | 7.62 | 6.54 | 8.75 | 8.03 |
| Price to cash flow ratio | 24.58 | 17.27 | 38.66 | 4.79 | 20.89 | 22.39 | 33.88 | 47.01 | 16.34 | 66.83 | 20.34 | 21.22 | 23.71 | 69.53 | 39.79 | 44.10 | 28.04 | 37.19 | 49.82 | 22.93 |
| Enterprise value | 2475Cr | 2004Cr | 1452Cr | 851Cr | 2319Cr | 3078Cr | 2719Cr | 1731Cr | 3451Cr | 9577Cr | 7151Cr | 7137Cr | 8229Cr | 13280Cr | 16321Cr | 19676Cr | 18441Cr | 14122Cr | 17233Cr | 15625Cr |
| Enterprise value to EBITDA ratio | 17.94 | 12.32 | 9.42 | 5.67 | 10.64 | 21.40 | 13.99 | 9.31 | 14.30 | 24.88 | 16.44 | 20.39 | 16.16 | 22.95 | 27.72 | 27.42 | 21.60 | 17.06 | 26.35 | 20.62 |
| Debt to equity ratio | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.04 | 0.04 | 0.06 | 0.04 | 0.03 | 0.03 |
| Return on equity % | 19.77 | 27.21 | 62.42 | 38.63 | 14.44 | 15.65 | 14.96 | 33.56 | 18.77 | 7.63 | 14.75 | 14.70 | 14.11 | 15.07 | 15.89 | 17.19 | 23.30 | 20.55 | 16.21 | 19.65 |
Pfizer Ltd Ratios
The Pfizer Ltd Ratios page provides a complete fundamental analysis of Pfizer Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Pfizer Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.
Pfizer Ltd (NSE: PFIZER, BSE: 500680) is currently trading at ₹4020.70, with a market capitalization of ₹18476.82Cr. As a major player in the Health technology sector and Pharmaceuticals: major industry, Pfizer Ltd remains a key stock for fundamental analysis using Pfizer Ltd Ratios.
Pfizer Ltd Ratios: Valuation Overview
Price to Earnings Ratio (P/E)
The Pfizer Ltd P/E ratio currently stands at 23.86, making it one of the most tracked metrics in Pfizer Ltd Ratios.
Historically, the Pfizer Ltd P/E ratio has shown strong fluctuations:
- 2024: 23.86
- 2023: 34.80
- 2022: 25.40
- 2021: 32.50
- 2020: 41.57
The decline in Pfizer Ltd P/E ratio suggests improving earnings relative to stock price.
Price to Book Ratio (P/B)
The Pfizer Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 4.34.
Historical P/B trend:
- 2024: 4.34
- 2023: 5.34
- 2022: 4.94
- 2021: 6.95
Pfizer Ltd is trading at a premium to its book value, indicating strong market confidence.
Price to Sales Ratio (P/S)
The Pfizer Ltd P/S ratio currently stands at 8.03, an important part of Pfizer Ltd Ratios for revenue valuation.
Historical P/S ratio:
- 2024: 8.03
- 2023: 8.75
- 2022: 6.54
- 2021: 7.62
A stable or declining Pfizer Ltd P/S ratio indicates cautious market sentiment.
Pfizer Ltd Price to Cash Flow Ratio (P/CF)
The Pfizer Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 22.93.
Historical Pfizer Ltd Price to Cash Flow Ratio:
- 2024: 22.93
- 2023: 49.82
- 2022: 37.19
- 2021: 28.04
- 2020: 44.10
The declining Pfizer Ltd Price to Cash Flow Ratio suggests improving cash flow strength.
Pfizer Ltd Enterprise Value Ratios
Enterprise Value (EV)
The Pfizer Ltd EV currently stands at ₹15625Cr, representing the total company valuation including debt.
Historical EV trend:
- 2024: 15625Cr
- 2023: 17233Cr
- 2022: 14122Cr
- 2021: 18441Cr
Pfizer Ltd enterprise value consolidation suggests stable valuation.
EV/EBITDA Ratio
The Pfizer Ltd EV/EBITDA ratio is currently 20.62, a key metric in Pfizer Ltd Ratios to assess valuation relative to earnings.
Historical EV/EBITDA:
- 2024: 20.62
- 2023: 26.35
- 2022: 17.06
- 2021: 21.60
Stable Pfizer Ltd EV/EBITDA indicates balanced valuation.
Pfizer Ltd Financial Strength Ratios
Debt to Equity Ratio (D/E)
The Pfizer Ltd D/E ratio is currently 0.03, reflecting leverage and financial stability.
Historical D/E:
- 2024: 0.03
- 2023: 0.03
- 2022: 0.04
- 2021: 0.06
Pfizer Ltd maintains a strong balance sheet with low debt levels.
Return on Equity (ROE %)
The Pfizer Ltd ROE currently stands at 19.65%, showing profitability and capital efficiency.
Historical ROE:
- 2024: 19.65
- 2023: 16.21
- 2022: 20.55
- 2021: 23.30
Pfizer Ltd maintains stable profitability levels.
Pfizer Ltd Ratios Analysis Summary
The Pfizer Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Pfizer Ltd stock is undervalued, fairly valued, or overvalued.
Tracking Pfizer Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.